Monitoring peripheral edema in heart failure patients and a normal cohort using molecular chemical imaging (MCI)

Heart failure (HF) has a significant impact on patient outcomes and health care costs. Objective monitoring of pitting edema level of a HF patient may help clinicians reduce the volume of patient re-admissions. To address this, ChemImage is developing a Molecular Chemical Imaging (MCI) device for noninvasive measurement of peripheral edema level in HF patients. In an initial clinical study, edema grade was predicted in HF patients with 86% accuracy. Results from a follow-up clinical trial demonstrating the capability of MCI to monitor changes in a HF patient’s peripheral edema over time during the course of treatment will be presented.